Johnson & Johnson said the first commercial installation of its Ottava robotic surgery system will go to Memorial Hermann-Texas Medical Center in Houston1,2. The placement marks the beginning of J&J's early access commercial program for the soft-tissue robot, which received de novo authorization from the Food and Drug Administration in July for use in 10 general surgery procedures within the upper abdomen.
Tim Schmid, J&J's worldwide chairman for medtech, said in a statement that the milestone is a significant step toward the company's ambition to lead in surgical robotics.
The FDA authorization covers Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication, and hiatal hernia repair. Ottava's four arms are integrated into a standard-sized surgical table to save operating-room space. Memorial Hermann-Texas Medical Center served as a clinical trial site in the investigational device exemption program that supported the robot's regulatory authorization.
The commercial agreement landed in the same week that rival Medtronic revealed expanded FDA clearance for its Hugo robot in upper abdominal general surgery. Hugo had gained its initial FDA clearance in December for urologic procedures such as prostate removal. Both J&J and Medtronic are now taking on longtime robotic surgery leader Intuitive Surgical in the U.S. market.
ANALYSIS The near-simultaneous regulatory and commercial milestones for Ottava and Hugo compress the timeline for direct competition in upper-abdominal general surgery, a segment Intuitive Surgical has dominated. J&J's choice to begin its rollout at a site that already participated in Ottava's clinical program gives the company a controlled environment for early commercial feedback before broader distribution.